

Francesco Paneni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/709934/francesco-paneni-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106
papers

3,725
citations

31
h-index

59
g-index

121
ext. papers

4,633
ext. citations

5.5
avg. IF

5.81
L-index

#	Paper	IF	Citations
106	Diabetes and heart failure: from disease mechanisms to personalized care.. <i>Minerva Cardiology and Angiology</i> , 2022 , 70, 341-343	2.4	0
105	The Epigenome in Atherosclerosis. <i>Handbook of Experimental Pharmacology</i> , 2021 , 1	3.2	0
104	Inflammation in Metabolic Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 742178	5.4	7
103	Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease-From Bench to Bedside. <i>Frontiers in Physiology</i> , 2021 , 12, 755060	4.6	2
102	Assessment and pathophysiology of microvascular disease: recent progress and clinical implications. <i>European Heart Journal</i> , 2021 , 42, 2590-2604	9.5	24
101	Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system. <i>Cardiovascular Research</i> , 2021 , 117, 2275-2288	9.9	3
100	Cell-specific epigenetic changes in atherosclerosis. <i>Clinical Science</i> , 2021 , 135, 1165-1187	6.5	3
99	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. <i>European Heart Journal</i> , 2021 , 42, 1940-1958	9.5	13
98	Characterisation of haemodynamic and metabolic abnormalities in the heart failure spectrum: the role of combined cardiopulmonary and exercise echocardiography stress test. <i>Minerva Cardiology and Angiology</i> , 2021 ,	2.4	9
97	Disentangling the epigenetic landscape in cardiovascular patients: a path toward personalized medicine. <i>Minerva Cardiology and Angiology</i> , 2021 , 69, 331-345	2.4	1
96	Deletion of fibroblast activation protein provides atheroprotection. <i>Cardiovascular Research</i> , 2021 , 117, 1060-1069	9.9	4
95	Epigenetic Remodeling in Obesity-Related Vascular Disease. <i>Antioxidants and Redox Signaling</i> , 2021 , 34, 1165-1199	8.4	10
94	A Once-and-Done Approach to the Lifelong Reduction of Elevated Cholesterol. <i>European Heart Journal</i> , 2021 , 42, 3820-3821	9.5	1
93	Exploring RNA biomarkers in patients with acute myocarditis. <i>European Heart Journal</i> , 2021 , 42, 3425-3436	9.5	0
92	Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?. <i>European Heart Journal</i> , 2021 , 42, 4211-4212	9.5	0
91	Adeno-Associated Virus-Mediated Gain-of-Function mPCSK9 Expression in the Mouse Induces Hypercholesterolemia, Monocytosis, Neutrophilia, and a Hypercoagulative State. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 718741	5.4	1
90	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. <i>Cardiovascular Research</i> , 2021 ,	9.9	2

89	The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1. <i>Atherosclerosis</i> , 2020 , 304, 30-38	3.1	6
88	Epigenetic Control of Mitochondrial Function in the Vasculature. <i>Frontiers in Cardiovascular Medicine</i> , 2020 , 7, 28	5.4	23
87	Regression of left ventricular hypertrophy with SGLT2 inhibitors. <i>European Heart Journal</i> , 2020 , 41, 3433-3436	9.5	5
86	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis - Central role of macrophage scavenger receptor 1. <i>Journal of Molecular and Cellular Cardiology</i> , 2020 , 139, 24-32	5.8	13
85	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. <i>European Heart Journal</i> , 2020 , 41, 3884-3899	9.5	29
84	The vascular epigenome in patients with obesity and type 2 diabetes: opportunities for personalized therapies. <i>Vascular Biology (Bristol, England)</i> , 2020 , 2, H19-H28	2.9	4
83	Sex-related differences in the ageing brain: time for precision medicine?. <i>Cardiovascular Research</i> , 2020 , 116, 1246-1248	9.9	0
82	Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 168-180	7	8
81	New Mechanisms of Vascular Dysfunction in Cardiometabolic Patients: Focus on Epigenetics. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2020 , 27, 363-371	2.9	8
80	Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. <i>Frontiers in Immunology</i> , 2020 , 11, 569358	8.4	1
79	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020 , 127, 1261-1273	15.7	12
78	Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood-brain barrier integrity: a translational study. <i>European Heart Journal</i> , 2020 , 41, 1575-1587	9.5	26
77	An overview of the molecular mechanisms underlying development and progression of bicuspid aortic valve disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2019 , 132, 146-153	5.8	15
76	GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials. <i>Vascular Pharmacology</i> , 2019 , 115, 64-68	5.9	4
75	PCSK9 in diabetes: sweet, bitter or sour?. <i>European Heart Journal</i> , 2019 , 40, 369-371	9.5	5
74	Thromboembolic Events Following Atrial Fibrillation Cardioversion and Ablation: What's the Culprit?. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	
73	Atrial fibrillation in the cardiometabolic patient. <i>Minerva Medica</i> , 2019 , 110, 157-167	2.2	9
72	Interleukin-1 β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	37

71	Epigenetic modulation of tenascin C in the heart: implications on myocardial ischemia, hypertrophy and metabolism. <i>Journal of Hypertension</i> , 2019 , 37, 1861-1870	1.9	15
70	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. <i>European Heart Journal</i> , 2019 , 40, 997-1008	9.5	40
69	Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 709-727	3.9	36
68	The epigenetic landscape in the cardiovascular complications of diabetes. <i>Journal of Endocrinological Investigation</i> , 2019 , 42, 505-511	5.2	15
67	Epigenetic processing in cardiometabolic disease. <i>Atherosclerosis</i> , 2019 , 281, 150-158	3.1	23
66	Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity. <i>European Heart Journal</i> , 2019 , 40, 383-391	9.5	33
65	Sirtuin 5 as a novel target to blunt blood-brain barrier damage induced by cerebral ischemia/reperfusion injury. <i>International Journal of Cardiology</i> , 2018 , 260, 148-155	3.2	34
64	Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena. <i>European Heart Journal</i> , 2018 , 39, 4150-4158	9.5	49
63	Epigenetics and cardiovascular regenerative medicine in the elderly. <i>International Journal of Cardiology</i> , 2018 , 250, 207-214	3.2	29
62	Empagliflozin across the stages of diabetic heart disease. <i>European Heart Journal</i> , 2018 , 39, 371-373	9.5	6
61	Hyperglycaemia-induced epigenetic changes drive persistent cardiac dysfunction via the adaptor p66. <i>International Journal of Cardiology</i> , 2018 , 268, 179-186	3.2	32
60	The elevation of circulating fibroblast growth factor 23 without kidney disease does not increase cardiovascular disease risk. <i>Kidney International</i> , 2018 , 94, 49-59	9.9	43
59	Authors Reply to Dr. Schmitz and Dr. Brand comments on "Epigenetics and Cardiovascular Regenerative Medicine in the Elderly". <i>International Journal of Cardiology</i> , 2018 , 257, 274	3.2	
58	Predictors of Successful Ultrasound Guided Femoral Vein Cannulation in Electrophysiological Procedures. <i>Journal of Atrial Fibrillation</i> , 2018 , 11, 2083	0.8	2
57	Image integration guided ablation of left outflow tract ventricular tachycardia: Is coronary angiography still necessary?. <i>Indian Pacing and Electrophysiology Journal</i> , 2018 , 18, 73-75	1.5	1
56	Post-ischaemic administration of the murine Canakinumab-surrogate antibody improves outcome in experimental stroke. <i>European Heart Journal</i> , 2018 , 39, 3511-3517	9.5	33
55	The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1952-1967	15.1	262
54	A call for safety during electrophysiological procedures: US in, why not US out?. <i>Europace</i> , 2017 , 19, 2048	3.9	2

53	Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting. <i>American Heart Journal</i> , 2017 , 188, 118-126	4.9	8
52	Endothelial LOX-1 activation differentially regulates arterial thrombus formation depending on oxLDL levels: role of the Oct-1/SIRT1 and ERK1/2 pathways. <i>Cardiovascular Research</i> , 2017 , 113, 498-507	9.9	22
51	Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA Levels. <i>Diabetes</i> , 2017 , 66, 2472-2482	9.9	105
50	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Medicine</i> , 2017 , 130, S18-S29	2.4	37
49	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. <i>American Journal of Cardiology</i> , 2017 , 120, S17-S27	3	54
48	Residual SYNTAX score following coronary artery bypass grafting. <i>European Journal of Cardio-thoracic Surgery</i> , 2017 , 51, 547-553	3	4
47	Stakeholders in non-Vitamin K antagonist oral anticoagulants prescription: the case of Italy. <i>Europace</i> , 2016 , 18, 788	3.9	2
46	Pin1 inhibitor Juglone prevents diabetic vascular dysfunction. <i>International Journal of Cardiology</i> , 2016 , 203, 702-7	3.2	35
45	Reprogramming ageing and longevity genes restores paracrine angiogenic properties of early outgrowth cells. <i>European Heart Journal</i> , 2016 , 37, 1733-7	9.5	22
44	MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart. <i>European Heart Journal</i> , 2016 , 37, 572-6	9.5	102
43	Ageing, metabolism and cardiovascular disease. <i>Journal of Physiology</i> , 2016 , 594, 2061-73	3.9	164
42	Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 150-8		106
41	Molecular pathways of arterial aging. <i>Clinical Science</i> , 2015 , 128, 69-79	6.5	31
40	Epidemiology, Definition, and Diagnosis of Diabetes Mellitus		2
39	Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. <i>European Heart Journal</i> , 2015 , 36, 516-26a	9.5	29
38	Targeting prolyl-isomerase Pin1 prevents mitochondrial oxidative stress and vascular dysfunction: insights in patients with diabetes. <i>European Heart Journal</i> , 2015 , 36, 817-28	9.5	57
37	Diabetes and cardiovascular disease: let's push forward with translational research. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 407-11	2.6	2
36	DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 471-8	2.6	12

35	Targeting chromatin remodeling to prevent cardiovascular disease in diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2015 , 16, 531-43	2.6	24
34	Hyperglycemia: a bad signature on the vascular system. <i>Cardiovascular Diagnosis and Therapy</i> , 2015 , 5, 403-6	2.6	12
33	Role of oxidative stress in endothelial insulin resistance. <i>World Journal of Diabetes</i> , 2015 , 6, 326-32	4.7	43
32	Risk Stratification 2015 , 69-83		
31	Environment, Epigenetic Changes, and Cardiovascular Damage 2015 , 35-47		
30	Abnormal regulation of renin angiotensin aldosterone system is associated with right ventricular dysfunction in hypertension. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 188-94	3.8	7
29	Insulin resistance, diabetes, and cardiovascular risk. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 419	6	99
28	Intrinsic bleeding risk in patients with uninterrupted oral anticoagulation undergoing cardiac implantable electronic device procedures: a pilot study. <i>International Journal of Cardiology</i> , 2014 , 176, 1420-2	3.2	1
27	p66(Shc)-induced redox changes drive endothelial insulin resistance. <i>Atherosclerosis</i> , 2014 , 236, 426-9	3.1	23
26	2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: established knowledge and evidence gaps. <i>Diabetes and Vascular Disease Research</i> , 2014 , 11, 5-10	3.3	18
25	Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. <i>European Heart Journal</i> , 2014 , 35, 2839-48	9.5	58
24	Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes. <i>Cardiovascular Diagnosis and Therapy</i> , 2014 , 4, 324-32	2.6	22
23	Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. <i>Atherosclerosis</i> , 2013 , 230, 191-7	3.1	54
22	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. <i>European Heart Journal</i> , 2013 , 34, 2444-52	9.5	213
21	Mechanisms of Cardiovascular Aging. <i>Current Translational Geriatrics and Experimental Gerontology Reports</i> , 2013 , 2, 275-283		1
20	AngiomiR-126 expression and secretion from circulating CD34(+) and CD14(+) PBMCs: role for proangiogenic effects and alterations in type 2 diabetics. <i>Blood</i> , 2013 , 121, 226-36	2.2	146
19	Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. <i>International Journal of Cardiology</i> , 2013 , 167, 2482-9	3.2	29
18	Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. <i>Circulation</i> , 2013 , 127, 1229-40, e1-21	16.7	73

17	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. <i>European Heart Journal</i> , 2013 , 34, 2436-43	9.5	597
16	SIRT1, p66(Shc), and Set7/9 in vascular hyperglycemic memory: bringing all the strands together. <i>Diabetes</i> , 2013 , 62, 1800-7	0.9	73
15	Deletion of the ageing gene p66(Shc) reduces early stroke size following ischaemia/reperfusion brain injury. <i>European Heart Journal</i> , 2013 , 34, 96-103	9.5	56
14	Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. <i>Hypertension Research</i> , 2013 , 36, 36-42	4.7	22
13	Relation between right and left ventricular function in patients undergoing chronic dialysis. <i>Journal of Cardiovascular Medicine</i> , 2013 , 14, 289-95	1.9	14
12	p66 Shc as the engine of vascular aging. <i>Current Vascular Pharmacology</i> , 2012 , 10, 697-9	3.3	18
11	Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. <i>Circulation Research</i> , 2012 , 111, 278-89	15.7	169
10	Impact of dialysis modality on the appropriateness of left ventricular mass in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2011 , 149, 250-252	3.2	11
9	Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. <i>Current Hypertension Reports</i> , 2011 , 13, 318-24	4.7	25
8	Right ventricular dysfunction in patients with end-stage renal disease. <i>American Journal of Nephrology</i> , 2010 , 32, 432-8	4.6	58
7	A case of thrombolysis in acute pulmonary embolism with right atrial thrombus: comparing current and past guidelines. <i>Internal and Emergency Medicine</i> , 2009 , 4, 497-500	3.7	1
6	Novel Lipids Targets in the Era of Metabolic Syndrome. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2009 , 16, 93-100	2.9	1
5	Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. <i>Clinical Science</i> , 2009 , 116, 467-77	6.5	106
4	The Growing Importance of Socioeconomic Aspects in Cardiovascular Disease. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 139-144	2.9	
3	Upcoming Challenges for Training in Cardiology. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 201-206	2.9	
2	The Microvolt T-Wave Alternans Test. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007 , 14, 213-219		
1	The Apelin/APJ System. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006 , 13, 159-162	2.9	